Could a nasal spray of stem cell 'Messages' ease Schizophrenia's toughest symptoms?

NCT ID NCT07485751

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase pilot study will test whether a nasal spray containing exosomes from human dental stem cells is safe and feasible for people with treatment-resistant schizophrenia who have persistent negative symptoms like social withdrawal and lack of emotion. Fifteen long-term inpatients will receive the spray twice weekly for two months. The main goal is to check for side effects and see if participants can stick with the treatment, while also looking for any hints of symptom improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

exosomes from human dental follicle stem cells

What this could lead to

If safe and effective, this could point toward a new way to ease negative symptoms like social withdrawal and lack of motivation in people with hard-to-treat schizophrenia.

What could go wrong

This is a very early, small pilot study with only 15 people. It is designed mainly to check safety, not to prove it works. The treatment may not help symptoms or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT-RESISTANT SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia treatment-refractory schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••